Abstract:Mechanistic Target of Rapamycin (mTOR) binds the small metabolite inositol hexakisphosphate (IP ) as shown in structures of mTOR, however it remains unclear if IP , or any other inositol phosphate species, can activate mTOR kinase activity. Here, we show that multiple, exogenously added inositol phosphate species (IP , IP , IP and IP ) can all enhance the ability of mTOR and mTORC1 to auto-phosphorylate and incorporate radiolabeled phosphate into peptide substrates in kinase reactions. Although IP did not affect the apparent K of mTORC1 for ATP, monitoring kinase activity over longer reaction times showed increased product formation, suggesting inositol phosphates stabilize an active form of mTORC1 . The effects of IP on mTOR were reversible, suggesting IP bound to mTOR can be exchanged dynamically with the free solvent. Interestingly, we also observed that IP could alter mTOR solubility and electrophoretic mobility in SDS-PAGE in the presence of manganese, suggesting divalent cations may play a role in inositol phosphate regulation of mTOR. Together, these data suggest for the first time that multiple inositol phosphate species (IP , IP and IP ) can dynamically regulate mTOR and mTORC1 by promoting a stable, active state of the kinase. Our data suggest that studies of the dynamics of inositol phosphate regulation of mTOR are well justified.

What problem does this paper attempt to address?

The core problem that this paper attempts to solve is to explore whether various inositol phosphate species can activate or enhance the kinase activity of mTOR (Mechanistic Target of Rapamycin) and its complex mTORC1. Specifically, the researchers hope to understand whether inositol phosphate species such as IP6 (inositol hexakisphosphate), IP5, IP4, and IP3 can directly regulate the catalytic activity of mTOR, and how these small molecules affect the stability and solubility of mTOR. ### Main problem decomposition: 1. **Effect of inositol phosphate on mTOR kinase activity**: - Is there evidence that exogenously added IP6, IP5, IP4, and IP3 can enhance the autophosphorylation of mTOR and mTORC1 and their ability to phosphorylate peptide substrates? - Do these inositol phosphate species affect their activity by changing the affinity (\( K_M \)) of mTOR for ATP or peptide substrates? 2. **Effect of inositol phosphate on mTOR stability**: - Can exogenously added inositol phosphate increase the stability and solubility of mTOR in in vitro reactions? - Can IP6 enhance the stability and electrophoretic mobility of mTOR by binding to manganese ions (Mn²⁺)? 3. **Kinetic characteristics of inositol phosphate binding to mTOR**: - Is the binding of inositol phosphate to mTOR dynamic and reversible? That is, can IP6 be exchanged with mTOR in solution? - Does this dynamic binding mean that mTOR can "sense" changes in the concentration of inositol phosphate in the surrounding environment? ### Overview of research results: - **Enhanced kinase activity**: The study found that exogenously added IP6, IP5, IP4, and IP3 can significantly enhance the autophosphorylation of mTOR and mTORC1 and their ability to phosphorylate peptide substrates, and this enhancement is dose - dependent. - **No significant \( K_M \) change**: Although IP6 and other inositol phosphates enhance the catalytic activity of mTOR, they do not significantly change the \( K_M \) of mTOR for ATP or peptide substrates, indicating that these small molecules mainly play a role by stabilizing the active conformation of mTOR. - **Increased mTOR solubility and stability**: IP6 significantly increases the solubility of mTOR in the presence of manganese ions and prolongs the active state of mTOR, allowing mTOR to maintain high catalytic activity in long - term reactions. - **Dynamic binding characteristics**: Experiments show that the binding of IP6 to mTOR is dynamic and reversible, which means that mTOR can adjust its active state according to changes in the IP6 concentration in the environment. ### Conclusion: This study shows that various inositol phosphate species (especially IP6, IP5, and IP4) can enhance the kinase activity of mTOR by stabilizing its active conformation, and this regulatory effect is dynamic and reversible. In addition, IP6 can also increase the solubility and stability of mTOR in the presence of manganese ions. These findings provide a new perspective for in - depth understanding of the role of inositol phosphate in cell signal transduction and metabolic regulation.

Multiple inositol phosphate species enhance stability of active mTOR

Inositol Hexakisphosphate Kinase 1 (ip6k1) Regulates Inositol Synthesis in Mammalian Cells

Amino Acid Regulation of TOR Complex 1.

Inositol Biosynthesis Is Fine-Tuned By Inositol Pyrophosphates In Saccharomyces Cerevisiae

Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.

Phosphoproteome Profiling Revealed The Importance Of Mtor Inhibition On Cdk1 Activation To Further Regulate Cell Cycle Progression

Furthering the Design and the Discovery of Small Molecule ATP-competitive Mtor Inhibitors As an Effective Cancer Treatment

Understanding inositol pyrophosphate metabolism and function: Kinetic characterization of the DIPPs

Cross-talk between Sirtuin and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in the Regulation of S6 Kinase 1 (S6K1) Phosphorylation

Inositol Pyrophosphates: Signaling Molecules with Pleiotropic Actions in Mammals

Biochemical and Pharmacological Inhibition of Mtor by Rapamycin and an ATP-Competitive Mtor Inhibitor

Protein interaction network analysis of mTOR signaling reveals modular organization

Dynamic modelling of the PI3K/MTOR signalling network uncovers biphasic dependence of mTORC1 activity on the mTORC2 subunit SIN1

The Mammalian Target of Rapamycin Complex 2 Controls Folding and Stability of Akt and Protein Kinase C

Quantitative phosphoproteomic analyses identify STK11IP as a lysosome-specific substrate of mTORC1 that regulates lysosomal acidification

Targeting mTOR globally in cancer: thinking beyond rapamycin.

Biochemical, Cellular, and in Vivo Activity of Novel Atp-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate

Integrated proteasomal and lysosomal activity shape mTOR-regulated proteome remodeling

Protein kinase N controls a lysosomal lipid switch to facilitate nutrient signalling via mTORC1

mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets